Literature DB >> 30023392

Optimal regimen of cisplatin in squamous cell carcinoma of head and neck yet to be determined.

Xiuning Le1, Ehab Y Hanna2.   

Abstract

Entities:  

Year:  2018        PMID： 30023392      PMCID： PMC6036002          DOI： 10.21037/atm.2018.05.10

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  33 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  Scheduling cisplatin and radiotherapy in the treatment of squamous cell carcinomas of the head and neck: a modelling approach.

Authors:  L Marcu; E Bezak; I Olver
Journal:  Phys Med Biol       Date:  2006-07-12       Impact factor: 3.609

3.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

4.  Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014.

Authors:  Amanda-Louise Fenger Carlander; Christian Grønhøj Larsen; David Hebbelstrup Jensen; Emilie Garnæs; Katalin Kiss; Luise Andersen; Caroline Holkmann Olsen; Maria Franzmann; Estrid Høgdall; Susanne K Kjær; Bodil Norrild; Lena Specht; Elo Andersen; Thomas van Overeem Hansen; Finn Cilius Nielsen; Christian von Buchwald
Journal:  Eur J Cancer       Date:  2016-11-23       Impact factor: 9.162

5.  Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial.

Authors:  B Jeremic; Y Shibamoto; B Stanisavljevic; L Milojevic; B Milicic; N Nikolic
Journal:  Radiother Oncol       Date:  1997-04       Impact factor: 6.280

6.  Radiotherapy with concomitant continuous cisplatin infusion for unresectable tumors of the upper aerodigestive tract: results of a phase I study.

Authors:  J M Bachaud; E Chatelut; P Canal; N Albin; E Yardeni; J M David; E Serrano; N Daly-Schveitzer
Journal:  Am J Clin Oncol       Date:  1997-02       Impact factor: 2.339

7.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Authors:  Jean-Pierre Pignon; Aurélie le Maître; Emilie Maillard; Jean Bourhis
Journal:  Radiother Oncol       Date:  2009-05-14       Impact factor: 6.280

8.  [Concomitant association of radiotherapy and chemotherapy (CDDP 4-6 mg/m2/daily in continuous i.v. administration) in locally advanced ORL tumors].

Authors:  J M Bachaud; N Albin; C Gay; E Chatelut; M Benchalal; J M David; A Boneu; E Serrano; P Canal; N Daly-Schveitzer
Journal:  Bull Cancer       Date:  1994-03       Impact factor: 1.276

9.  Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons.

Authors:  M A Khan; W H Tolleson; J D Gangemi; L Pirisi
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

10.  The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity.

Authors:  Din-Li Tsan; Chien-Yu Lin; Chung-Jan Kang; Shiang-Fu Huang; Kang-Hsing Fan; Chun-Ta Liao; I-How Chen; Li-Yu Lee; Hung-Ming Wang; Joseph Tung-Chieh Chang
Journal:  Radiat Oncol       Date:  2012-12-18       Impact factor: 3.481
View more
  7 in total

Review 1.  Mechanisms of Cisplatin-Induced Acute Kidney Injury: Pathological Mechanisms, Pharmacological Interventions, and Genetic Mitigations.

Authors:  Kristen Renee McSweeney; Laura Kate Gadanec; Tawar Qaradakhi; Benazir Ashiana Ali; Anthony Zulli; Vasso Apostolopoulos
Journal:  Cancers (Basel)       Date:  2021-03-29       Impact factor: 6.639

2.  Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments.

Authors:  Ki Hyun Yoo; Jason J Tang; Mohammad Abdur Rashid; Chang Hoon Cho; Ana Corujo-Ramirez; Jonghoon Choi; Mun Gyeong Bae; Danielle Brogren; John R Hawse; Xiaonan Hou; S John Weroha; Alfredo Oliveros; Lindsey A Kirkeby; Joseph A Baur; Mi-Hyeon Jang
Journal:  Cancer Res       Date:  2021-03-26       Impact factor: 12.701

3.  Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts.

Authors:  Wenhao Yao; Xu Qian; Sebastian Ochsenreither; Ferrone Soldano; Albert B DeLeo; Holger Sudhoff; Felix Oppel; Andreas Kuppig; Konrad Klinghammer; Andreas M Kaufmann; Andreas E Albers
Journal:  Cells       Date:  2021-02-28       Impact factor: 7.666

4.  Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients.

Authors:  Cosphiadi Irawan; Larangga Gempa Benbella; Andhika Rachman; Arif Mansjoer
Journal:  J Epidemiol Glob Health       Date:  2021-11-30

5.  Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine.

Authors:  M Parhizkar; P J T Reardon; A H Harker; R J Browning; E Stride; R B Pedley; J C Knowles; M Edirisinghe
Journal:  Nanoscale Adv       Date:  2020-01-27

6.  IL-2 Induces Transient Arrest in the G1 Phase to Protect Cervical Cancer Cells from Entering Apoptosis.

Authors:  María Del Carmen Lagunas-Cruz; Arturo Valle-Mendiola; Jonathan Trejo-Huerta; Leticia Rocha-Zavaleta; María de Lourdes Mora-García; Adriana Gutiérrez-Hoya; Benny Weiss-Steider; Isabel Soto-Cruz
Journal:  J Oncol       Date:  2019-09-26       Impact factor: 4.375

7.  Effects of wogonoside on invasion and migration of lung cancer A549 cells and angiogenesis in xenograft tumors of nude mice.

Authors:  Yubo Yan; Lei Yao; Haobo Sun; Sainan Pang; Xianglong Kong; Su Zhao; Shidong Xu
Journal:  J Thorac Dis       Date:  2020-04       Impact factor: 2.895
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.